Literature DB >> 25557351

Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition.

Charlotte Höybye1.   

Abstract

AIM: Growth hormone (GH) treatment is a relatively new concept in adults, and the knowledge of its long-term effects is limited. We studied ten men with Prader-Willi Syndrome (PWS) after more than 5 years of GH treatment.
METHODS: Study participants underwent a detailed physical examination, including blood tests. Five had received GH as childhood and five had started GH as adults.
RESULTS: The total duration of GH treatment was 16 ± 4 years in the childhood PWS group and 15 ± 1 years in the adulthood PWS group. Their respective mean ages were 27 ± 4 years and 44 ± 4 years, mean heights were 178 ± 11 cm and 156 ± 5 cm, and mean body mass indexes were 32.4 ± 10.3 kg/m(2) and 28.9 ± 4.6 kg/m(2) . There were no differences in body composition between the groups and all lipids and insulin-like growth factor 1 were normal or close to normal. Four had well-controlled type 2 diabetes. The GH doses in the childhood and adulthood groups were 0.4 mg and 0.3 mg, respectively.
CONCLUSION: Men with PWS who received GH treatment displayed positive effects on body composition independent of when the GH treatment had started. Only patients who gained weight developed diabetes. The duration of GH treatment should balance the benefits and observed side effects. ©2014 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Body composition; Growth hormone deficiency; Long-term growth hormone treatment; Prader-Willi Syndrome

Mesh:

Substances:

Year:  2015        PMID: 25557351     DOI: 10.1111/apa.12898

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

Review 1.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

Review 2.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

3.  Epigenomic-basis of Preemptive Medicine for Neurodevelopmental Disorders.

Authors:  Takeo Kubota; Kunio Miyake; Natsuyo Hariya; Kazuki Mochizuki
Journal:  Curr Genomics       Date:  2015-06       Impact factor: 2.236

Review 4.  Growth Hormone Therapy in Adults with Prader-Willi Syndrome.

Authors:  Karen S Vogt; Jill E Emerick
Journal:  Diseases       Date:  2015-04-16

Review 5.  Obesity management in Prader-Willi syndrome: current perspectives.

Authors:  Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-04       Impact factor: 3.168

6.  A multidisciplinary approach to the clinical management of Prader-Willi syndrome.

Authors:  Jessica Duis; Pieter J van Wattum; Ann Scheimann; Parisa Salehi; Elly Brokamp; Laura Fairbrother; Anna Childers; Althea Robinson Shelton; Nathan C Bingham; Ashley H Shoemaker; Jennifer L Miller
Journal:  Mol Genet Genomic Med       Date:  2019-01-29       Impact factor: 2.183

7.  Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome.

Authors:  Charlotte Höybye; Anthony J Holland; Daniel J Driscoll
Journal:  Orphanet J Rare Dis       Date:  2021-02-08       Impact factor: 4.123

Review 8.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

9.  Prevalence and risk factors for type 2 diabetes mellitus with Prader-Willi syndrome: a single center experience.

Authors:  Aram Yang; Jinsup Kim; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Orphanet J Rare Dis       Date:  2017-08-30       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.